[Clinical experience with bencyclane in the treatment of vascular obliterations in the limbs].
D000328:Adult; D001161:Arteriosclerosis / Q000188:drug therapy; D001775:Blood Circulation / Q000187:drug effects; D003508:Cycloheptanes / Q000627:therapeutic use*; D005650:Fumarates / Q000627:therapeutic use; D005734:Gangrene / Q000150:complications; D006801:Humans; D007866:Leg / Q000098:blood supply*; D008297:Male; D010276:Parasympatholytics / Q000627:therapeutic use*; D011437:Propylamines / Q000627:therapeutic use*; D011928:Raynaud Disease / Q000188:drug therapy; D013919:Thromboangiitis Obliterans / Q000188:drug therapy; D014652:Vascular Diseases / Q000188:drug therapy*; D014665:Vasodilator Agents / Q000008:administration & dosage
D003508:Cycloheptanes; D005650:Fumarates; D010276:Parasympatholytics; D011437:Propylamines; D014665:Vasodilator Agents
Klinische Erfahrungen mit Bencyclan bei Behandlung obliterierender Erkrankungen der Extremitäten-Gefässe.